Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) saw unusually-high trading volume on Tuesday . Approximately 193,313 shares changed hands during trading, a decline of 3% from the previous session’s volume of 198,310 shares.The stock last traded at $3.80 and had previously closed at $3.72.

DRNA has been the subject of a number of research reports. Stifel Nicolaus reduced their target price on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, June 30th. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Sunday, June 26th. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Thursday, May 12th. Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Finally, Jefferies Group restated a “buy” rating and issued a $19.00 price target on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $11.85.

The stock has a 50 day moving average price of $3.38 and a 200-day moving average price of $4.23. The company’s market capitalization is $71.60 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.09. Analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.17) earnings per share for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.